• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Flexion Therapeutics

Flexion reports data from Phase II bilateral osteoarthritis trial

October 22, 2018 By Sarah Faulkner

Flexion Therapeutics - updated logo

Flexion Therapeutics (NSDQ:FLXN) touted data today from a Phase II trial assessing the bilateral dosing of its extended-release triamcinolone acetonide injection in people with bilateral osteoarthritis. The study found that bilateral injections of Flexion’s Zilretta therapy resulted in lower plasma concentrations of triamcinolone acetonide compared to immediate-release triamcinolone acetonide in crystalline suspension (TAcs). The company also […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Wall Street Beat Tagged With: Flexion Therapeutics

Flexion touts interim data from Ph3 trial of osteoarthritis injection

April 27, 2018 By Sarah Faulkner

Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis injection, Zilretta. The company’s injectable suspension is an extended-release formulation of triamcinolone acetonide designed for patients with osteoarthritis of the knee. Top-line results from Flexion’s trial showed that 95% of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Flexion Therapeutics

SureFire Medical names pharma vet Szela as president, CEO | Personnel Moves – Jan. 26, 2018

January 26, 2018 By Sarah Faulkner

Surefire Medical

SureFire Medical has named pharma veteran Mary Szela as its president, CEO and board member, succeeding founder James Chomas, who has served as the company’s chief executive and president since 2009. Chomas will assume the role of chief technology officer and oncology strategy officer, focusing his efforts on the the company’s oncology drug-delivery tech. “Immune […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, cingulatetherapeutics, Eyenovia Inc., Flexion Therapeutics, milestonescientific, Ocular Therapeutix, PolyPid, surefiremedical

Flexion CEO: Setting Zilretta up to succeed with a history lesson

December 1, 2017 By Sarah Faulkner

Flexion CEO Mike Clayman

Locally acting therapies are like a religion to Flexion Therapeutics (NSDQ:FLXN) co-founder & CEO Dr. Mike Clayman, who spent decades at Eli Lilly (NYSE:LLY) with the company’s co-founder, Dr. Neil Bodick, watching promising compounds fail in late-stage trials on the heels of unanticipated safety results. “That’s part of the reason, not the whole reason but part of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Eli Lilly & Co., Flexion Therapeutics

After FDA nod, Flexion launches osteoarthritis injection

November 20, 2017 By Sarah Faulkner

Flexion Therapeutics (NSDQ:FLXN) today launched its Zilretta therapy designed to help patients manage pain associated with osteoarthritis of the knee. The Burlington, Mass.-based company’s extended-release intra-articular injection combines a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix using Flexion’s microsphere technology. The FDA approved Zilretta last month after granting it fast track status in 2015. […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Orthopedics, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Flexion Therapeutics

FDA accepts Flexion’s NDA for osteoarthritis steroid injection

February 7, 2017 By Sarah Faulkner

Flexion Therapeutics (NSDQ:FLXN) said today that the FDA accepted its New Drug Application for Zilretta – its extended-release steroid injection. The Burlington, Mass.-based company won Fast Track status from the watchdog for its osteoarthritis injection in 2015. Flexion touts Zilretta as the 1st intra-articular, extended-release therapy for patients with knee osteoarthritis pain. The injection uses microsophere technology […]

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Pain Management, Regulatory/Compliance Tagged With: Flexion Therapeutics

Flexion seeks FDA nod for osteoarthritis steroid injection

December 12, 2016 By Sarah Faulkner

Flexion Therapeutics (NSDQ:FLXN) said today that it submitted a new drug application to the FDA for its extended-release steroid injection Zilretta. The Burlington, Mass.-based company won Fast Track status from the watchdog for its osteoarthritis injection last year. The new drug application is based on data from a pivotal phase III clinical trial evaluating Zilretta in […]

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Pain Management, Regulatory/Compliance Tagged With: Flexion Therapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS